Screening for genetic mutations could substantially reduce the risk of hypersensitivity reactions involving skin rash among people starting nevirapine, according to a late-breaker report at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention this month in Kuala Lumpur.
http://www.hivandhepatitis.com/hiv-aids/hiv-aids-topics/hiv-treatment/4203-ias-2013-genetic-testing-lowers-risk-of-nevirapine-skin-rash
http://www.hivandhepatitis.com/hiv-aids/hiv-aids-topics/hiv-treatment/4203-ias-2013-genetic-testing-lowers-risk-of-nevirapine-skin-rash
No comments:
Post a Comment